此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券 交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓 閣下於加科思藥業集團有限公司之全部股份，應立即將本通函及隨附代表 委任表格送交買主或承讓人或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買主或 承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 建議授出一般授權 以發行股份及購回股份、 建議重選董事、 股東週年大會通告 除文義另有所指外，本封面頁所用詞彙與本通函「釋義」一節所界定者具相同涵義。 加科思藥業集團有限公司謹訂於2025年6月10日（星期二）下午二時正假座中國北京市北京經濟技 術開發區經海三路1 ...

Core Viewpoint - The pharmaceutical market, particularly innovative drug companies, is experiencing significant growth, with substantial support from policies, leading to the emergence of high-performing stocks similar to Changchun Gaoxin. Group 1: Market Performance - The Hong Kong innovative drug index has increased from 859 points at the beginning of the year to 1284 points, representing a 50% rise [1] - The mainland innovative drug index has risen from a low of 948 to a high of 1156, showing a 22% increase, indicating a significant lag compared to Hong Kong [1] Group 2: Stock Performance - Several stocks in the Hong Kong innovative drug sector have seen substantial gains, such as: - Kintor Pharmaceutical rising from 2.48 to 19.78 HKD - Akeso increasing from 1.2 to 4.3 HKD - CanSino Biologics moving from 2 to 8.73 HKD - CStone Pharmaceuticals growing from 0.8 to 3.89 HKD - Innovent Biologics increasing from 26.45 to 105.5 HKD [4] - The current bullish trend in Hong Kong's innovative drug sector is viewed as just the beginning, with expectations of a long-term market cycle lasting 50 years [4] Group 3: Historical Comparisons - Historical data from 2005 to 2007 shows that Hong Kong real estate stocks typically initiated their upward trends over six months before A-share stocks, with A-share stocks generally experiencing greater increases [5] - Examples include: - China Overseas Land rising from 2.29 to 21.95 HKD - Vanke increasing from 6.76 to 33.82 HKD - Deep Zhenye rising from 19.90 to 271.8 HKD [5] - The patterns observed in the real estate sector may provide insights into the potential trajectory of mainland innovative drug stocks, suggesting a possible follow-up to the Hong Kong market's performance [5]

Major Events - Jin'an Industrial (02292) received a privatization offer from its controlling shareholder at a premium of approximately 30%, with resumption of trading on May 12 [1] - Jingtai Holdings (02228) plans to acquire 90% of Shanghai Siwei Medical for 250 million yuan, aiming to create an AI-enabled remote electrocardiogram diagnosis platform [1] - China Investment and Financing (01226) is in contact with MCHKI to explore several potential corporate activities following unusual stock price movements [1] - Qiu Tai Technology (01478) reported camera module sales of 33.229 million units in April, an increase of 8.4% month-on-month but a decrease of 20.1% year-on-year [1] - Stone Pharmaceutical Group (01093) received approval for clinical trials of SYH2046 in the United States [1] - Fosun Pharma (02196) subsidiary Junji Health obtained FDA approval for drug clinical trials [1] - Rongchang Bio (09995) received approval for the marketing of Aidiqi® for treating HER2-positive advanced breast cancer with liver metastasis in China [1] - Livzon Pharmaceutical (01513) received approval for the marketing of injectable aripiprazole microspheres [1] - GAC Group (02238) reported April automobile production of 108,600 units, a year-on-year decline of 25.74% [2] - China Overseas Development (00688) reported contract property sales of approximately 20.164 billion yuan in April, a year-on-year decrease of 7.5% [2] Share Buybacks/Reductions - China Hongqiao (01378) repurchased 19.667 million shares for 273 million HKD on May 9 [1] - AIA Group (01299) repurchased 1.5 million shares for 92.1915 million HKD on May 9 [1] - Cathay Securities (02611) repurchased 1.6906 million A-shares for 29.3356 million yuan on May 9 [1] - Times Electric (03898) repurchased 610,300 shares for 19.7008 million HKD on May 9 [1] - East Asia Bank (00023) acquired 52.8 million shares from Sumitomo Mitsui Banking Corporation [1] - Shandong Molong (00568) saw shareholder Zhimo Holdings reduce its holdings by 28.81 million H-shares [1] Operating Performance - Longyuan Power (00916) achieved a power generation volume of 6.9064 million MWh in April, a year-on-year increase of 4.85% [2] - New天绿色能源 (00956) reported a power generation volume of 1.4778 million MWh in April, a year-on-year increase of 16.91% [2] - Jianye Real Estate (00832) achieved a total property contract sales amount of 2.71 billion yuan in the first four months, a year-on-year increase of 4.8% [2] - China Overseas Hongyang Group (00081) reported a cumulative contract sales amount of 9.556 billion yuan in the first four months, a year-on-year decrease of 14.1% [2] - Times China Holdings (01233) reported a cumulative contract sales amount of approximately 1.81 billion yuan in the first four months, a year-on-year decrease of 29.87% [2] - Agile Property Holdings (01813) reported a pre-sale amount of 509 million yuan in April, a year-on-year decrease of 47.5% [2] - Greenland Hong Kong (00337) reported contract sales of approximately 880 million yuan in the first four months, a year-on-year decrease of 69.3% [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 建議對現行組織章程大綱及章程細則進行修訂 並採納經修訂及重述組織章程大綱及章程細則 本公告乃由加科思藥業集團有限公司（「本公司」）根據《香港聯合交易所有限公司證券上市 規則》（「《上市規則》」）第13.51(1)條作出。 本公司董事（「董事」）會（「董事會」）建議對本公司現行組織章程大綱及章程細則（「組織章 程大綱及章程細則」）作出若干修訂（「建議修訂」），以便（其中包括）(i)使組織章程大綱及 章程細則符合《上市規則》有關擴大無紙化上市機制的最新監管規定及相關修訂；(ii)容許 以實體會議、混合會議方式或僅以電子方式召開及舉行股東大會，使本公司在舉行股東 大會的方式上更具靈活性；(iii)允許 ...

（股份代號：1167） 自願公告 SHP2抑制劑SITNEPROTAFIB聯用研究數據發表於學術期刊 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） Sitneprotafib（JAB-3312）是一種高選擇性的SHP2抑制劑，具有同類最佳潛力。加科思目前 正在中國、美國和歐洲進行多項JAB-3312的臨床試驗，包括和KRAS G12C抑制劑glecirasib 等項目的聯合用藥試驗。與glecirasib聯合用藥的三期臨床試驗於2024年2月在中國國家藥 品監督管理局藥品評審中心獲批。 香港聯合交易所有限公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） JACOBIO PHARMACEUTICALS GROUP CO., LTD. 本公司股東及潛在投資者在買賣本公司股份時務請審慎行事。 承董事會命 加科思藥業集團有限公司 董事長 王印祥 香港，2025年4月30日 自願公告 一致行動人士的權益變動 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以令其股東及潛在投資者獲悉本公司一致行動人士的權益變動原因。 因部分已從本集團離職的人士（「離職人士」）持有本公司的股份權益已經不再被視為本公 司一致行動人士（「一致行動人士」），截至本公告日期，一致行動人士可行使的投票權由 約26.67%變為約25.21%，且一致行動人士仍為本公司最大單一股東集團。 本公司收到離職人士的通知，為 ...

Core Viewpoint - The Hong Kong pharmaceutical stocks have experienced a decline, with notable drops in several companies' share prices, indicating a bearish trend in the sector [1] Company Performance - Kangfang Biotech (09926.HK) saw a significant drop of 15.07% in its share price [1] - Yiming Oncology-B (01541.HK) decreased by 9.75% [1] - Zai Lab (09688.HK) fell by 6.43% [1] - Akeso-B (01167.HK) experienced a decline of 5.37% [1] - Terns Pharmaceuticals-B (02137.HK) dropped by 5% [1]

JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加科思藥業集團有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 1167) 25 April 2025 Dear non-registered shareholder(s), Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 1 March 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Jacobio Pharmaceuticals Group Co., Ltd. (the "Company") is writing to re ...

JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加科思藥業集團有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 1167) 25 April 2025 Dear registered shareholder(s), Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications (Note 1) With reference to the notification letter dated 1 March 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Jacobio Pharmaceuticals Group Co., Ltd. (the "Company") is writing ...

Financial Performance - Revenue increased from RMB 63.5 million in the year ended December 31, 2023, to RMB 155.7 million for the year ended December 31, 2024, representing a growth of 145.2%[14] - Gross profit increased from RMB 3.2 million for the year ended December 31, 2023, to RMB 155.7 million for the year ended December 31, 2024, a rise of 4,765.6%[109] - Other income rose from RMB 7.5 million in 2023 to RMB 14.3 million in 2024, primarily due to increased government subsidies related to R&D projects[110] - The adjusted loss for the year ended December 31, 2024, was RMB (145,727) thousand, a significant improvement from RMB (337,022) thousand in 2023, representing a reduction of approximately 57%[123] - The net cash used in operating activities for the year ended December 31, 2024, was RMB 74.1 million, a decrease of RMB 290.1 million compared to RMB 364.2 million for the year ended December 31, 2023[126] - The net cash generated from investing activities for the year ended December 31, 2024, was RMB 256.2 million, an increase of RMB 303.6 million from RMB 47.4 million in 2023[126] - The net cash generated from financing activities for the year ended December 31, 2024, was RMB 21.3 million, a decrease of RMB 224.4 million compared to RMB 245.7 million in 2023[128] - As of December 31, 2024, the company's cash and cash equivalents amounted to RMB 1,174.5 million, a slight decrease from RMB 1,197.9 million as of December 31, 2023[130] Research and Development - Research and development expenses decreased from RMB 372.3 million to RMB 330.2 million, a reduction of 11.3%[15] - The company aims to enhance its R&D platforms and has identified a unique STING agonist molecule for its iADC candidate products[102] - The company is focusing on advancing core projects like Pan-KRAS and iADC, targeting approximately 25% of cancer patients with KRAS mutations[11] - The company aims to establish strategic partnerships with leading multinational companies to enhance the success rate of its drug candidates[34] - The company is actively pursuing collaborations with academic institutions and other biotech firms to advance its research objectives and product pipeline[157] Drug Development and Clinical Trials - The company submitted a New Drug Application (NDA) for the KRAS G12C inhibitor glecirasib, marking a significant milestone in its commercialization journey[10] - Glecirasib's NDA for ≥2L NSCLC was submitted to CDE in May 2024, with priority review status, and is expected to receive approval in H1 2025[21] - The pivotal trial for Glecirasib combined with Sitneprotafib in 1L NSCLC has been approved by CDE and initiated on August 7, 2024[21] - Glecirasib has received ODD from the FDA for PDAC in April 2024 and from EMA in October 2024[22] - The company has demonstrated efficient clinical development, completing the entire clinical development of Glecirasib in less than three years[41] - The company is the first to initiate a first-line NSCLC Phase III trial in China, comparing an oral combination therapy with chemotherapy and immunotherapy, targeting KRAS G12C mutation patients with PD-L1 <1%[46] Strategic Partnerships and Collaborations - A collaboration agreement with Eli Lilly for glecirasib and SHP2 inhibitor (JAB-3312) was established, with a total transaction value of RMB 900 million[10] - The rights for Glecirasib and Sitneprotafib in Greater China were licensed to Elysium for up to RMB 900 million in upfront and milestone payments, plus a double-digit percentage of net sales[23] - The company has established an exclusive licensing agreement with Elysium for Glecirasib and Sitneprotafib in the Greater China region, retaining rights outside this area[55] Management and Governance - The company has implemented a 2021 equity incentive plan to attract and retain key personnel, providing additional rewards to employees[139] - The audit committee consists of one non-executive director and two independent non-executive directors, ensuring compliance with accounting standards and internal controls[140] - The company has established effective mechanisms to ensure the board receives independent advice and recommendations[174] - The board consists of three executive directors, one non-executive director, and three independent non-executive directors, ensuring strong independence[171] - The company has adopted the Corporate Governance Code as its own governance code, complying with all applicable provisions as of December 31, 2024[167] Employee and Organizational Structure - As of December 31, 2024, the group had a total of 257 employees, down from 301 employees in 2023[139] - Total salary costs for the year ending December 31, 2024, amounted to RMB 153.5 million, a decrease from RMB 174.1 million for the year ending December 31, 2023[139] - The company has a strong focus on expanding its research and development capabilities in innovative drug therapies for neurological and oncological diseases[157][163] - The company has established a competitive compensation structure, including bonuses and stock-based compensation, to incentivize employees[139] Innovation and Technology - The company is focused on developing cutting-edge KRAS combinations for single-agent and rational combination therapies to address significant unmet medical needs in tumors with KRAS mutations[99] - The iADC projects utilize proprietary STING agonist payloads to tackle challenges related to low response rates of current ICI therapies and toxicity issues associated with traditional ADCs[101] - The company has developed a proprietary STING agonist iADC, with the clinical candidate HER2-STING iADC named JAB-BX467 expected to be nominated in the second half of 2024 and an IND application planned for 2026[92] Market Position and Competitive Landscape - The company has established significant competitive barriers in the KRAS inhibitor field, with over 80+ priority filings compared to competitors' 10+ and an earliest priority date of 2021[98] - The company aims to lead in the development of innovative cancer therapies targeting KRAS, with a diverse pipeline including glecirasib (KRAS G12C inhibitor JAB-21822) and JAB-22000 (KRAS G12D inhibitor)[97] - The KRASi ADC platform aims to expand to pan-KRAS inhibitors, targeting broader KRAS mutations like G12V and G13D, with expectations to surpass existing small molecule drugs in efficacy[84]